Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate. The potential Food and Drug ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
Breast cancer: 0.48% (one in 207 women); 88% Leukemia: 0.13% (one in 799 women); 46% Melanoma of the skin: 0.21% (one in 484 women); 91% Non-Hodgkin's lymphoma: 0.09% (one in 1147 women); 59% ...
Expansion cohorts include ovarian cancer, all tumor types and T-cell lymphoma (including CTCL). The dose escalation in Phase 1 part B has been completed and the Phase 2a dose expansion study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback